Jason Buxbaum, MHSA, project manager, V-BID Health; and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council, discuss low-value services, their financial impact, what states are doing to address them, and challenges with addressing them.
As conversations surrounding rising healthcare costs persist, the idea of addressing low-value services has caught the attention of health professionals nationwide. Value-Based Insurance Design (V-BID) Health’s Task Force on Low-Value Care has identified a top 5 list of low-value clinical services that can be targeted.
We spoke with Jason Buxbaum, MHSA, project manager, V-BID Health, about which 5 low-value services topped the list, the financial impact they have, and how states are attempting to address them.
Once low-value services are identified, healthcare professionals face another challenge: turning conversation into something actionable. We discussed the challenges with addressing these low-value services with Buxbaum and Robert Dubois, MD, PhD, chief scientific officer, National Pharmaceutical Council.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Dr John M. O'Brien Highlights Critical Role of Rebates in Employer Benefit Choices
August 5th 2024John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council, discusses his recent study, which sheds light on how important rebates are when choosing benefits for employers and who advises employers on these choices.
Read More